SBIR Phase I: Well-defined PEGylated multiblock polyamino acids for protein drug delivery

该小型企业创新研究第一阶段项目有助于解决使用蛋白质药物的治疗技术所面临的两个问题：（i）目前蛋白质药物的载体在分子水平上是不均匀的，（ii）蛋白质药物的疗效因目前用于蛋白质药物给药的载体而降低。提供了一种创新的合成技术，可以绝对控制此类载体的分子量，从而产生均匀的载体系统。这些新的载体系统与蛋白质药物的相互作用是最小的，因此对蛋白质药物的功效没有不利影响。此外，该技术是对现有技术的实质性改进，因为它不依赖于金属催化剂，并且它是scaleable.The更广泛的影响，这项研究是，开发量身定制的药物递送载体的技术，容易采用新的蛋白质药物的特定生化要求。制药公司正在不断识别，开发和制造新的治疗肽和蛋白质。所有这些新型蛋白质药物都需要一种能够适应其脆弱性质的运载工具。因此，所提出的技术是对社会需求的响应，即，对新型药物递送系统的关键需求，以跟上制药工业的发展。Alamanda Polymers提出的药物输送系统具有这种潜力，并引起学术和国家研究机构以及生物技术公司的兴趣。该奖项由2009年美国复苏和再投资法案（公法111-5）资助。

This Small Business Innovation Research Phase I project contributes solutions to two problems faced by therapeutic techniques using protein drugs: (i) current carriers for protein drugs are nonuniform on a molecular level and (ii) the efficacy of protein drugs diminishes by the carriers currently used for administering protein drugs. An innovative synthetic technique is provided that allows absolute control over the molecular weight of such carriers, hence generating uniform carrier systems. The interaction of these new carrier systems with the protein drugs is minimal and will therefore have no detrimental effect on the efficacy of the protein drug. Moreover, this technique is a substantial improvement over current techniques, since it does not rely on metal catalysts and it is scaleable.The broader impacts of this research are, to develop tailor-made drug delivery vehicles by technologies that readily adopt to the specific biochemical requirements of new protein drugs. Pharma companies are constantly identifying, developing and manufacturing novel therapeutic peptides and proteins. All of these novel protein drugs need a delivery vehicle that accommodates their fragile nature. Hence, the proposed technology is responsive to societal needs, that is, a critical demand for new types of drug delivery systems to keep pace with the developments of the pharma industry. The drug delivery systems proposed by Alamanda Polymers hold this potential and are of interest to academic and national research institutions and biotechnology companies.This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5).